Abstract
This study describes point-of-sale prices for orally administered anticancer drugs offered through Medicare Part D and out-of-pocket changes in spending as a result of decreasing coinsurance and price changes between 2010 and 2019.
MeSH terms
-
Administration, Oral
-
Antineoplastic Agents / economics*
-
Formularies as Topic
-
Health Expenditures / statistics & numerical data*
-
Medicare Part D / economics*
-
Prescription Drugs / economics
-
Prescription Fees / statistics & numerical data*
-
United States
Substances
-
Antineoplastic Agents
-
Prescription Drugs